$TSVT
2seventy bio, Inc.

2023 Q4 Form 10-Q Financial Statement

#000186078223000113 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $10.68M $12.03M
YoY Change -80.98% -10.25%
Cost Of Revenue $3.147M $551.0K
YoY Change -79.46% 46.15%
Gross Profit $7.537M $11.48M
YoY Change -81.55% -11.88%
Gross Profit Margin 70.54% 95.42%
Selling, General & Admin $16.20M $13.00M
YoY Change -13.37% -33.69%
% of Gross Profit 214.95% 113.25%
Research & Development $51.22M $51.32M
YoY Change 3.86% -16.88%
% of Gross Profit 679.54% 446.88%
Depreciation & Amortization $3.030M $2.770M
YoY Change 30.32% 16.53%
% of Gross Profit 40.2% 24.12%
Operating Expenses $67.47M $64.32M
YoY Change -0.87% -20.93%
Operating Profit -$59.94M -$77.97M
YoY Change 120.26% 14.04%
Interest Expense $3.648M $3.626M
YoY Change 144.67% 225.79%
% of Operating Profit
Other Income/Expense, Net -$534.0K $2.704M
YoY Change -120.85% -533.33%
Pretax Income -$56.82M -$71.64M
YoY Change 145.35% 5.54%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$56.82M -$71.64M
YoY Change 145.53% 5.54%
Net Earnings / Revenue -531.84% -595.3%
Basic Earnings Per Share -$1.40
Diluted Earnings Per Share -$1.11 -$1.40
COMMON SHARES
Basic Shares Outstanding 50.62M shares 50.46M shares
Diluted Shares Outstanding 51.18M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $217.0M $250.6M
YoY Change -18.51% -22.44%
Cash & Equivalents $74.96M $90.23M
Short-Term Investments $142.0M $160.4M
Other Short-Term Assets $7.365M $7.100M
YoY Change -46.05% -50.25%
Inventory
Prepaid Expenses $7.365M $7.120M
Receivables $13.41M $19.50M
Other Receivables $0.00 $0.00
Total Short-Term Assets $237.8M $277.3M
YoY Change -20.98% -20.65%
LONG-TERM ASSETS
Property, Plant & Equipment $58.15M $60.68M
YoY Change 4.33% 30.08%
Goodwill $0.00 $0.00
YoY Change -100.0% -100.0%
Intangibles $6.594M $6.771M
YoY Change -9.7% -9.47%
Long-Term Investments $4.816M $33.70M
YoY Change 240.59% 2295.17%
Other Assets $38.14M $37.90M
YoY Change -0.65% -0.98%
Total Long-Term Assets $327.7M $363.6M
YoY Change -7.9% 1.18%
TOTAL ASSETS
Total Short-Term Assets $237.8M $277.3M
Total Long-Term Assets $327.7M $363.6M
Total Assets $565.4M $640.8M
YoY Change -13.89% -9.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.028M $5.307M
YoY Change -16.37% -33.52%
Accrued Expenses $38.35M $49.70M
YoY Change -41.76% -21.05%
Deferred Revenue $15.40M $13.03M
YoY Change 413.43%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $59.78M $68.01M
YoY Change -25.08% -14.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.416M $2.409M
YoY Change 0.79% -0.25%
Total Long-Term Liabilities $2.416M $2.409M
YoY Change 0.79% -0.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $59.78M $68.01M
Total Long-Term Liabilities $2.416M $2.409M
Total Liabilities $310.1M $334.4M
YoY Change -10.42% -13.27%
SHAREHOLDERS EQUITY
Retained Earnings -$511.2M -$454.4M
YoY Change 74.09% 67.98%
Common Stock $5.000K $5.000K
YoY Change 25.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $255.3M $306.4M
YoY Change
Total Liabilities & Shareholders Equity $565.4M $640.8M
YoY Change -13.89% -9.59%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$56.82M -$71.64M
YoY Change 145.53% 5.54%
Depreciation, Depletion And Amortization $3.030M $2.770M
YoY Change 30.32% 16.53%
Cash From Operating Activities -$63.60M -$21.51M
YoY Change 14.63% -64.7%
INVESTING ACTIVITIES
Capital Expenditures $1.071M $2.740M
YoY Change -66.17% -120.42%
Acquisitions
YoY Change
Other Investing Activities $48.96M $18.80M
YoY Change 1758.81% -127.3%
Cash From Investing Activities $47.89M $16.05M
YoY Change -9101.88% -119.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 253.0K -70.00K
YoY Change 9.05% -140.0%
NET CHANGE
Cash From Operating Activities -63.60M -21.51M
Cash From Investing Activities 47.89M 16.05M
Cash From Financing Activities 253.0K -70.00K
Net Change In Cash -15.45M -5.530M
YoY Change -72.3% -96.13%
FREE CASH FLOW
Cash From Operating Activities -$63.60M -$21.51M
Capital Expenditures $1.071M $2.740M
Free Cash Flow -$64.67M -$24.25M
YoY Change 10.26% -48.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
551000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
0 usd
CY2022Q4 us-gaap Goodwill
Goodwill
12056000 usd
CY2023Q3 tsvt Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
0 usd
CY2022Q4 tsvt Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
3744000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
68008000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
79794000 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16077000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5000000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
247890000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
259008000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2409000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2397000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
334384000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
346199000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50616000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37928000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37928000 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
640806000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19610000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53213000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60749000 usd
CY2023Q3 tsvt Income Loss From Collaborative Arrangements
IncomeLossFromCollaborativeArrangements
0 usd
CY2022Q3 tsvt Income Loss From Collaborative Arrangements
IncomeLossFromCollaborativeArrangements
0 usd
tsvt Income Loss From Collaborative Arrangements
IncomeLossFromCollaborativeArrangements
0 usd
tsvt Income Loss From Collaborative Arrangements
IncomeLossFromCollaborativeArrangements
-9642000 usd
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 reporting_unit
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50616000 shares
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
761728000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
606986000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-916000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2877000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-454395000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293647000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
306422000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
310466000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
656665000 usd
CY2023Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
5859000 usd
CY2022Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
7903000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
64265000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
18425000 usd
CY2023Q3 us-gaap Revenues
Revenues
12034000 usd
CY2022Q3 us-gaap Revenues
Revenues
13408000 usd
us-gaap Revenues
Revenues
89703000 usd
us-gaap Revenues
Revenues
35319000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51315000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58155000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
179541000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
188591000 usd
CY2023Q3 tsvt Manufacturing Costs Under Commercial Arrangements
ManufacturingCostsUnderCommercialArrangements
4408000 usd
CY2022Q3 tsvt Manufacturing Costs Under Commercial Arrangements
ManufacturingCostsUnderCommercialArrangements
3584000 usd
tsvt Manufacturing Costs Under Commercial Arrangements
ManufacturingCostsUnderCommercialArrangements
11672000 usd
tsvt Manufacturing Costs Under Commercial Arrangements
ManufacturingCostsUnderCommercialArrangements
10832000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13004000 usd
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
8614000 usd
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
0 usd
us-gaap Restructuring Charges
RestructuringCharges
8614000 usd
us-gaap Restructuring Charges
RestructuringCharges
0 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
377000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2099000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1252000 usd
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
54000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
50000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
180000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
181000 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
12056000 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
12056000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
90002000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
81776000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77968000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1441000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8159000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3477000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.67
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51179000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38573000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48566000 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1000 shares
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
116969000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
9859000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9666000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
451000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
927000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-47021000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
401324000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7740000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
520000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42089000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
367495000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9800000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
514000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-71638000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
306422000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
359822000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
165657000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9739000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2092000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-85711000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
447416000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-124000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9689000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-578000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-77420000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
378984000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12207000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
372000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-504000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-67879000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
323180000 usd
us-gaap Net Income Loss
NetIncomeLoss
-160748000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
180000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7255000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
27206000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
12056000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4881000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1074000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9611000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-753000 usd
tsvt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
16332000 usd
tsvt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
22076000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1015000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
422000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-16603000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1598000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-10016000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8927000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
21104000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
10000000 usd
tsvt Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
3744000 usd
tsvt Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
14361000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103263000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-180547000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12794000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19676000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
237151000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
115692000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
245899000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
147597000 usd
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
6983000 usd
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
1976000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
7000000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
2000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4029000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12253000 usd
tsvt Proceeds From Issuance Of Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts
117004000 usd
tsvt Proceeds From Issuance Of Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9859000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
165531000 usd
tsvt Proceeds From Stock Options Exercised And Stock Plans
ProceedsFromStockOptionsExercisedAndStockPlans
274000 usd
tsvt Proceeds From Stock Options Exercised And Stock Plans
ProceedsFromStockOptionsExercisedAndStockPlans
466000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127137000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165997000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19845000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2297000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92135000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128151000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90226000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127021000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1909000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1130000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92135000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1605000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2828000 usd
tsvt Accrued Stock Issuance Costs In Connection With Public Offering
AccruedStockIssuanceCostsInConnectionWithPublicOffering
35000 usd
tsvt Accrued Stock Issuance Costs In Connection With Public Offering
AccruedStockIssuanceCostsInConnectionWithPublicOffering
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-753000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-180547000 usd
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
1976000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
2000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12253000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2297000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130448000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128151000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1130000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128151000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div>Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
194378000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
339000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
194052000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
198754000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2108000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
196652000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
163870000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
295000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
1456000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
44000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
165326000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
339000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
91385000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
278000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
88674000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1830000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
180059000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2108000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Amortized Cost
RestrictedInvestmentsAvailableForSaleAmortizedCost
32666000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Accumulated Gross Unrealized Gain Before Tax
RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Accumulated Gross Unrealized Loss Before Tax
RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
594000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Excluding Accrued Interest
RestrictedInvestmentsAvailableForSaleExcludingAccruedInterest
32072000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Amortized Cost
RestrictedInvestmentsAvailableForSaleAmortizedCost
32880000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Accumulated Gross Unrealized Gain Before Tax
RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Accumulated Gross Unrealized Loss Before Tax
RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
1112000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Excluding Accrued Interest
RestrictedInvestmentsAvailableForSaleExcludingAccruedInterest
31768000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Continuous Unrealized Loss Position Less Than12 Months
RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
6460000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Continuous Loss Position Less Than12 Months Accumulated Loss
RestrictedInvestmentsAvailableForSaleContinuousLossPositionLessThan12MonthsAccumulatedLoss
28000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
25113000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Continuous Loss Position12 Months Or Longer Accumulated Loss
RestrictedInvestmentsAvailableForSaleContinuousLossPosition12MonthsOrLongerAccumulatedLoss
566000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Unrealized Loss Position
RestrictedInvestmentsAvailableForSaleUnrealizedLossPosition
31573000 usd
CY2023Q3 tsvt Restricted Investments Available For Sale Unrealized Loss Position Accumulated Loss
RestrictedInvestmentsAvailableForSaleUnrealizedLossPositionAccumulatedLoss
594000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Continuous Unrealized Loss Position Less Than12 Months
RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1942000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Continuous Loss Position Less Than12 Months Accumulated Loss
RestrictedInvestmentsAvailableForSaleContinuousLossPositionLessThan12MonthsAccumulatedLoss
27000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
29826000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Continuous Loss Position12 Months Or Longer Accumulated Loss
RestrictedInvestmentsAvailableForSaleContinuousLossPosition12MonthsOrLongerAccumulatedLoss
1085000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Unrealized Loss Position
RestrictedInvestmentsAvailableForSaleUnrealizedLossPosition
31768000 usd
CY2022Q4 tsvt Restricted Investments Available For Sale Unrealized Loss Position Accumulated Loss
RestrictedInvestmentsAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1112000 usd
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
800000 usd
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
300000 usd
CY2022Q3 tsvt Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
tsvt Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
CY2023Q3 tsvt Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
tsvt Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
CY2022Q4 tsvt Accrued Collaboration Research Costs Current
AccruedCollaborationResearchCostsCurrent
2005000 usd
CY2023Q3 tsvt Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
1584000 usd
CY2022Q4 tsvt Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
1619000 usd
CY2023Q3 tsvt Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
1157000 usd
CY2022Q4 tsvt Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
1498000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
114739000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
103573000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54058000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
47838000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60681000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55735000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15210000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14845000 usd
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8626000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13094000 usd
CY2023Q3 tsvt Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
5067000 usd
CY2022Q4 tsvt Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
17962000 usd
CY2023Q3 tsvt Accrued Collaboration Research Costs Current
AccruedCollaborationResearchCostsCurrent
2880000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
320000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
239000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2564000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3416000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
37408000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
54678000 usd
CY2023Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
9868000 usd
CY2023Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
3565000 usd
CY2023Q3 tsvt Purchase Obligation To Be Paid Year Two And Thereafter
PurchaseObligationToBePaidYearTwoAndThereafter
0 usd
CY2023Q3 us-gaap Purchase Obligation
PurchaseObligation
13433000 usd
CY2022Q2 tsvt Number Of Performance Obligations
NumberOfPerformanceObligations
2 performance_obligation
CY2018Q3 tsvt Number Of Accounting Units
NumberOfAccountingUnits
2 accounting_unit
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9800000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12207000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27206000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31635000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9800000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12207000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27206000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31635000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5704000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5704000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3969000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3969000 shares
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0 usd
us-gaap Restructuring Charges
RestructuringCharges
8614000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
795000 usd
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0 usd
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
7819000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
12100000 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
12100000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
12056000 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
12056000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
0 usd

Files In Submission

Name View Source Status
0001860782-23-000113-index-headers.html Edgar Link pending
0001860782-23-000113-index.html Edgar Link pending
0001860782-23-000113.txt Edgar Link pending
0001860782-23-000113-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsvt-20230930.htm Edgar Link pending
tsvt-20230930.xsd Edgar Link pending
tsvt-q3202310xqex311leschl.htm Edgar Link pending
tsvt-q3202310xqex312baird1.htm Edgar Link pending
tsvt-q3202310xqexhibit3211.htm Edgar Link pending
tsvt-20230930_def.xml Edgar Link unprocessable
tsvt-20230930_cal.xml Edgar Link unprocessable
tsvt-20230930_lab.xml Edgar Link unprocessable
tsvt-20230930_pre.xml Edgar Link unprocessable
tsvt-20230930_htm.xml Edgar Link completed